The European Investment Bank (EIB) is providing a loan of €40 million to Indivumed GmbH, a physician-led, global oncology company. The new funding will allow Indivumed to continue its development of a global database, supporting the work of cancer researchers by providing access to data from cancer patients, as well as investing in the latest technology to better understand complex cancer data.
The EFSI-backed funding will allow Indivumed to develop and validate new assays biomarker for the Biobank business and technology platforms. In addition, the Company is aiming at building a unique “Global Cancer Database Solution“ which would support cancer researchers worldwide by providing access to data from cancer patients, as well as bioinformatic tools to better understand complex cancer data.
The financing for this project is guaranteed by the European Fund for Strategic Investments (EFSI), the central pillar of the Investment Plan for Europe.
Vytenis Andriukaitis, Commissioner for Health and Food Safety, said: "Investments in health pay off. They help to increase the well-being of the entire population and of all individuals. The healthcare systems in many EU Member States have growing needs for investments in modern infrastructure, innovative technologies and new models of care. The investment in Indivumed shows that the EU Institutions are committed to assist Member States in doing just that. I am pleased that the EIB is signing this agreement today to help stakeholders in the health sector make more use of the Investment Plan for Europe for the benefit of our citizens."
Additional information and the latest Investment Plan Results are available on the Investment Plan website.